

Press Release

January 23, 2018



Pancreatic Cancer: a decisive partnership with Stanford University by 2018

A French start-up joins forces with one of the largest American Universities to find new therapeutic solutions for pancreatic cancer.

Selected as part of [the NETVA program](#) of the French Embassy in Washington in October 2017, Cell Constraint & Cancer was sent to California to present its project to investors, start-ups and academics in the San Francisco area. CELL CONSTRAINT & CANCER has teamed up with Guillem Pratx, Assistant Professor in Radio-Oncology and Medical Physics at [Stanford University](#), Director of the [Laboratory of Physical Oncology](#), to an agreement for animal testing to prove the action of a stress field on human pancreatic cancer grafted into the pancreas of mouse.

The objective of this experiment is to **obtain a significant reduction of the volume of the tumor** with the goal, subsequently, in the human patient, to make it operable. Recall that many *in vitro* experiments have reached this result; it will be the first proof of the action of a stress field on *in vivo* cancer ([see our Bibliography](#)).

As part of this partnership, a prototype magnetic field gradient generator owned by Stanford University will allow us to **achieve our ultimate research phase and begin industrial development with the implementation of human experiments in 4 to 5 years**. Complementary to the partnerships already established with the French CNRS, INSERM and G2ELab teams for Europe, this opportunity allows us to make our model more credible to US investors and significantly accelerate our research phase as early as 2018.

" Year 2018 marks a turning point in the life of our company. Obtaining our Proof of Efficiency on Pancreatic cancer will allow us to validate our initial hypotheses and to crown the patient and obstinate work we have been doing all these years. The partnership with Professor Guillem Pratx and Stanford University is a great opportunity for us, with a real scientific meeting, and means available ", says Barthélemy Brossel, CEO of CELL CONSTRAINT & CANCER.

" We are already engaged in writing a grant submission for the National Cancer Institute to conduct this experiment in our laboratory at Stanford University as soon as possible. We are really at the forefront of global research in the field of physical oncology ", says Guillem Pratx, director of the STANFORD UNIVERSITY Physical Oncology Laboratory.

Next Press Release: March 29, 2018 - Update on the activity of the 1st quarter of 2018

Find all the information about CELL CONSTRAINT & CANCER:

<http://new.cellconstraintcancer.com/en/home-2/>

About CELL CONSTRAINT & CANCER

Founded in 2009 by Rémy Brossel, medical oncologist and physicist, CELL CONSTRAINT & CANCER develops innovative treatments based upon [Physical Oncology](#), in a complementary approach to traditional oncology. Its technology addresses primarily non-metastatic non-operable tumors, such as cancer of the pancreas, brain, or liver. The company published in May 2016 a proof of the concept of the action of mechanical signals on a cancerous tumor grafted in vivo (read our article: [Mechanical signals inhibit growth of a grafted tumor in vivo: Proof of Concept](#)). To create these mechanical signals, CC & C has patented a technology that uses two medical devices: a magnetic field gradient generator located on the outside of the animal, and ferromagnetic nanoparticles brought around the tumor that will transform magnetic energy into mechanical energy.

The setting up of top-ranking partnerships (CNRS, INSERM, Stanford University) and the support of its shareholders since always allow it today to initiate a new phase of experiments on the animal called to provide the proof of efficiency of its technology on unmet medical needs.



CONTACT

Press

Barthélémy BROSSEL

Tel: +33 (0)6 50 22 79 64

Mail: barth.brossel@gmail.com

Shareholders & Investors

Christine GRAU

Tel: +33 (0)4 90 18 48 50

Mail: investisseurs@cellconstraintcancer.com